These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 23174195)

  • 21. Cost-effectiveness analysis of varicella vaccine as post-exposure prophylaxis in Hong Kong.
    Chui KS; Wu HL; You JH
    Scand J Infect Dis; 2014 Jan; 46(1):27-33. PubMed ID: 24228821
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and economic impact of various strategies for varicella immunity screening and vaccination of health care personnel.
    Baracco GJ; Eisert S; Saavedra S; Hirsch P; Marin M; Ortega-Sanchez IR
    Am J Infect Control; 2015 Oct; 43(10):1053-60. PubMed ID: 26138999
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-benefit analysis of universal varicella vaccination in the U.S. taking into account the closely related herpes-zoster epidemiology.
    Goldman GS
    Vaccine; 2005 May; 23(25):3349-55. PubMed ID: 15837242
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Childhood varicella-zoster virus vaccination in Belgium: cost-effective only in the long run or without exogenous boosting?
    Bilcke J; van Hoek AJ; Beutels P
    Hum Vaccin Immunother; 2013 Apr; 9(4):812-22. PubMed ID: 23321955
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modeling the impact of one- and two-dose varicella vaccination on the epidemiology of varicella and zoster.
    Brisson M; Melkonyan G; Drolet M; De Serres G; Thibeault R; De Wals P
    Vaccine; 2010 Apr; 28(19):3385-97. PubMed ID: 20199763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Economic evaluation of Varicella vaccination: results of a systematic review.
    Unim B; Saulle R; Boccalini S; Taddei C; Ceccherini V; Boccia A; Bonanni P; La Torre G
    Hum Vaccin Immunother; 2013 Sep; 9(9):1932-42. PubMed ID: 23823940
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Health Impact and Cost-effectiveness Assessment for the Introduction of Universal Varicella Vaccination in Switzerland.
    Heininger U; Pillsbury M; Samant S; Lienert F; Guggisberg P; Gani R; O'Brien E; Pawaskar M
    Pediatr Infect Dis J; 2021 Jun; 40(6):e217-e221. PubMed ID: 33872276
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Cost-effectiveness of varicella vaccination in Spanish adolescents].
    Peña-Rey I; Pérez-Farinós N; Cortés-García M; Amela-Heras C
    Gac Sanit; 2004; 18(4):287-94. PubMed ID: 15324639
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Varicella vaccination in England and Wales: cost-utility analysis.
    Brisson M; Edmunds WJ
    Arch Dis Child; 2003 Oct; 88(10):862-9. PubMed ID: 14500303
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of a routine varicella vaccination program for US children.
    Lieu TA; Cochi SL; Black SB; Halloran ME; Shinefield HR; Holmes SJ; Wharton M; Washington AE
    JAMA; 1994 Feb; 271(5):375-81. PubMed ID: 8283587
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessing the introduction of universal varicella vaccination in the Netherlands.
    Boot HJ; de Melker HE; Stolk EA; de Wit GA; Kimman TG
    Vaccine; 2006 Sep; 24(37-39):6288-99. PubMed ID: 16790302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The cost-effectiveness of routine childhood varicella vaccination in Germany.
    Banz K; Wagenpfeil S; Neiss A; Goertz A; Staginnus U; Vollmar J; Wutzler P
    Vaccine; 2003 Mar; 21(11-12):1256-67. PubMed ID: 12559807
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of the introduction of the pneumococcal polysaccharide vaccine in elderly Colombian population.
    Castañeda-Orjuela C; Alvis-Guzmán N; Paternina AJ; De la Hoz-Restrepo F
    Vaccine; 2011 Oct; 29(44):7644-50. PubMed ID: 21854825
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Modelling the impact of vaccination on the epidemiology of varicella zoster virus].
    Bonmarin I; Santa-Olalla P; Lévy-Bruhl D
    Rev Epidemiol Sante Publique; 2008 Oct; 56(5):323-31. PubMed ID: 18951741
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Varicella vaccination: to test or not to test.
    Black S
    Am J Med; 2000 Jun; 108(9):746-7. PubMed ID: 10924656
    [No Abstract]   [Full Text] [Related]  

  • 36. The value of varicella vaccination in healthy children: cost-benefit analysis of the situation in France.
    Coudeville L; Paree F; Lebrun T; Sailly J
    Vaccine; 1999 Jan; 17(2):142-51. PubMed ID: 9987148
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Varicella in French adolescents and adults: individual risk assessment and cost-effectiveness of routine vaccination.
    Hanslik T; Boëlle PY; Schwarzinger M; Carrat F; Freedberg KA; Valleron AJ; Flahault A
    Vaccine; 2003 Sep; 21(25-26):3614-22. PubMed ID: 12922090
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The case against universal varicella vaccination.
    Goldman GS
    Int J Toxicol; 2006; 25(5):313-7. PubMed ID: 16940003
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy].
    Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E
    Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of varicella serotesting versus presumptive vaccination of school-age children and adolescents.
    Lieu TA; Finkler LJ; Sorel ME; Black SB; Shinefield HR
    Pediatrics; 1995 May; 95(5):632-8. PubMed ID: 7724297
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.